Browsing Tag

Partnering

580 posts

Global Pharma Briefs: News from Asia, Australia, Europe, and the US
By

By
A roundup of developments from Australia (CSL), Germany (Bayer), India (Lupin, Wockhardt), and the US (GE). Australia CSL Partners with University of Queensland to Develop Coronavirus Vaccine CSL, a biotechnology…

BMS, BioMotiv Launch New Company, Anteros Pharmaceuticals
By

By
Bristol-Myers Squibb (BMS) and BioMotiv, a drug-development accelerator company that is focused on early-stage drug development, have launched Anteros Pharmaceuticals, a biopharmaceutical company focused on developing drugs for fibrotic and…

Coalition CEPI and GSK To Collaborate and Develop Coronavirus Vaccine
By

By
GlaxoSmithKline (GSK) and the Coalition for Epidemic Preparedness Innovations (CEPI), a public–private coalition that seeks to derail epidemics by speeding up the development of vaccines, agreed to collaborate on developing…

Global Pharma Briefs: News from Asia, Europe, Central America and the US
By

By
A roundup of developments from Dominican Republic and Germany, (Fresenius Kabi), India (Aurobindo), and the US (FDA). Dominican Republic Fresenius Kabi Expands Apheresis Sets Production Site in Dominican Republic Fresenius…

Global Pharma Briefs: News from Asia, Europe and the US
By

By
A roundup of developments and latest news from China (WuXi Biologics), India (Biocon), UK (AstraZeneca), US (Krystal Biotech). China WuXi Biologics Provides Update on Activities Relating to Coronavirus in China…

Global Pharma Briefs: News from Europe, Asia and the US
By

By
A roundup of developments and latest news from Germany (Bayer, WuXi Biologics), South Korea (Avacta, Daewoong), and US (Hikma, ANI Pharmaceuticals). Germany Bayer, WuXi Biologics in Acquisition Agreement for Bayer’s…

BI, Enleofen in $1 Bn-Plus Deal for Interleukin-11 Platform
By

By
Boehringer Ingelheim (BI) has acquired worldwide exclusive rights to the preclinical interleukin-11 (IL-11) platform of Enleofen Bio, a Singapore-based biopharmaceutical company, for developing therapies across a broad range of fibro-inflammatory…

Incyte, MorphoSys in $2-Bn Licensing Deal for Cancer Drug
By

By
MorphoSys, a Martinsried, Germany-based biopharmaceutical company, and Incyte, a Wilmington, Delaware-based, global biopharmaceutical company, have entered into a collaboration and license agreement to further develop and commercialize MorphoSys’ tafasitamab, a…

Merck & Co., Otsuka Form $2.5-Bn Research and License Pact
By

By
Merck & Co. has formed an exclusive worldwide research collaboration and license agreement, worth up to $2.5 billion with Taiho Pharmaceutical, a subsidiary of Otsuka Holdings, and Astex Pharmaceuticals (UK),…

Global Pharma Briefs: News from Asia, Europe and the US
By

By
A roundup of developments and latest news from China (BI, BeiGene), India (Biocon), Japan (Towa Pharmaceutical, Esteve), Singapore (Tessa Therapeutics), UK (AstraZeneca), and US (Aurobindo, Bausch Health).   China BI…